These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 25899797

  • 1. High Familial Correlation in Methylphenidate Response and Side Effect Profile.
    Gazer-Snitovsky M, Brand-Gothelf A, Dubnov-Raz G, Weizman A, Gothelf D.
    J Atten Disord; 2019 Jan; 23(2):135-139. PubMed ID: 25899797
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [Abstract] [Full Text] [Related]

  • 3. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [Abstract] [Full Text] [Related]

  • 4. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
    Efron D, Jarman F, Barker M.
    Pediatrics; 1997 Oct; 100(4):662-6. PubMed ID: 9310521
    [Abstract] [Full Text] [Related]

  • 5. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial.
    Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA.
    J Child Adolesc Psychopharmacol; 2004 Oct; 14(2):195-206. PubMed ID: 15319017
    [Abstract] [Full Text] [Related]

  • 6. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR, Hafezi P, Galeiha A, Hajiaghaee R, Akhondzadeh S.
    Acta Med Iran; 2012 Oct; 50(11):723-8. PubMed ID: 23292622
    [Abstract] [Full Text] [Related]

  • 7. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
    Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB.
    J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
    [Abstract] [Full Text] [Related]

  • 8. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD.
    Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, Joober R.
    BMC Psychiatry; 2011 Apr 21; 11():70. PubMed ID: 21510895
    [Abstract] [Full Text] [Related]

  • 9. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb 01; 34(1):76-80. PubMed ID: 19815048
    [Abstract] [Full Text] [Related]

  • 10. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LA.
    Arch Gen Psychiatry; 2007 Feb 01; 64(2):218-24. PubMed ID: 17283289
    [Abstract] [Full Text] [Related]

  • 11. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M.
    J Child Adolesc Psychopharmacol; 2006 Jun 01; 16(3):351-6. PubMed ID: 16768642
    [Abstract] [Full Text] [Related]

  • 12. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T, Patsopoulos NA, Weiser M.
    Cochrane Database Syst Rev; 2014 Sep 18; (9):CD005041. PubMed ID: 25230710
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.
    J Clin Psychiatry; 2008 Dec 18; 69(12):1938-47. PubMed ID: 19192455
    [Abstract] [Full Text] [Related]

  • 14. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D, Jarman F, Barker M.
    Pediatrics; 1997 Dec 18; 100(6):E6. PubMed ID: 9382907
    [Abstract] [Full Text] [Related]

  • 15. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov 18; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 16. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.
    Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, Inbar D, Steinberg T, Frisch A, Apter A, Weizman A.
    J Clin Psychiatry; 2003 Oct 18; 64(10):1163-9. PubMed ID: 14658963
    [Abstract] [Full Text] [Related]

  • 17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 18; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 18. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
    Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK.
    J Clin Psychiatry; 2007 Jan 18; 68(1):93-101. PubMed ID: 17284136
    [Abstract] [Full Text] [Related]

  • 19. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M, Hechtman L, Turgay A, Jain U, Quinn D, Ahmed TS, Yates T, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.
    J Child Adolesc Psychopharmacol; 2007 Oct 18; 17(5):675-88. PubMed ID: 17979587
    [Abstract] [Full Text] [Related]

  • 20. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
    Johnson KA, Barry E, Lambert D, Fitzgerald M, McNicholas F, Kirley A, Gill M, Bellgrove MA, Hawi Z.
    J Child Adolesc Psychopharmacol; 2013 Dec 18; 23(10):655-64. PubMed ID: 24350812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.